Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
We’re doubling down on Accrol despite downgrade disappointment

AJ Bell is an easy to use, award-winning platform Open an account
We've accounts to suit every investing need, and free guides and special offers to help you get the most from them.
You can get a few handy suggestions, or even get our experts to do the hard work for you – by picking one of our simple investment ideas.
All the resources you need to choose your shares, from market data to the latest investment news and analysis.
Funds offer an easier way to build your portfolio – we’ve got everything you need to choose the right one.
Starting to save for a pension, approaching retirement, or after an explainer on pension jargon? We can help.
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Our buy call on Accrol (ACRL:AIM) is 25.6% underwater following a profit warning (20 Oct 2021) from the toilet roll, tissue and kitchen roll maker.
Yet we’re minded to stay positive on the private label manufacturer, since the business is being buffeted by external factors rather than internal issues. Accrol has been transformed by chief executive Gareth Jenkins and has exciting longer-term growth potential, supported by the expansion of the major discounters.
Earnings for the year to next April will be lower than previously expected due to a time lag in passing on increased supply chain costs to customers. The HGV driver shortage, rising raw material prices and a slower than expected recovery in footfall for discounters have conspired to constrain Accrol’s sales and profit growth.
While forecasts have been downgraded, Accrol still expects to deliver revenue growth of 25% and a 20% improvement in adjusted EBITDA this year. And the company, which sells non-discretionary products, remains well placed to benefit from a recovery in tissue volumes as the effects of the pandemic unwind.
SHARES SAYS: Accrol’s profit warning is unfortunate, but we think the shares are oversold. Still a buy.
These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell.
Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.
Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.
The value of your investments can go down as well as up and you may get back less than you originally invested. We don't offer advice, so it's important you understand the risks, if you're unsure please consult a suitably qualified financial adviser. Tax treatment depends on your individual circumstances and rules may change. Past performance is not a guide to future performance and some investments need to be held for the long term.
Our website uses cookies to give you a better browsing experience.
You can choose to accept all cookies, or control which we use by clicking 'Manage cookies'. To learn more, read our cookie policy.